Foghorn Therapeutics Plans To Discontinue The Advancement Of FHD-286 Development In Uveal Melanoma Though The Company Says That Phase 1 Trial Data Support The Safety And Tolerability Profile Of FHD-286
Portfolio Pulse from Benzinga Newsdesk
Foghorn Therapeutics has announced plans to discontinue the development of FHD-286 for Uveal Melanoma. However, the company maintains that Phase 1 trial data supports the safety and tolerability profile of FHD-286.
June 28, 2023 | 11:12 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Foghorn Therapeutics' decision to discontinue FHD-286 development could potentially impact the company's stock negatively in the short term.
The discontinuation of a drug development, especially after Phase 1 trials, often leads to a negative market reaction as it represents a potential loss of future revenue and a setback in the company's pipeline. This could lead to a short-term decrease in Foghorn Therapeutics' stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100